TrialGynecologic oncology2023

Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.

Aaron M Praiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.